CIRC(01763) subsidiary BNCT boron drug submits IND application

CIRC (01763) announced that recently, the official website of the Drug Evaluation Center (CDE) of the National Medical Products Administration revealed that the subsidiary company of the company, Shenzhen Zhonghe Haidewei Biotechnology Co., Ltd. ("Zhonghe Haidewei"), has applied for "Boron [10B] FARNA" for injection, which has been officially accepted by the Drug Evaluation Center of the National Medical Products Administration, with acceptance number CXHL2501079. The "Boron [10B] FARNA" being developed by Zhonghe Haidewei has significant clinical advantages for tumors that are insensitive to radiotherapy, recurrent, difficult to treat, invasive, in the middle and late stages, and locally metastatic. The treatment course is short (only 1-2 times), with low toxicity and side effects, and integrates diagnosis and treatment, representing the development direction and frontier innovation of modern precision oncology. It provides a new treatment option for patients, promotes innovation and breakthroughs in the field of cancer treatment. The submission of the BNCT boron drug by Zhonghe Haidewei marks a breakthrough in the cooperative research and development of domestic BNCT technology in the medical device field, officially entering a new stage of clinical transformation. It injects new energy of nuclear technology into precise cancer treatment under the "Healthy China" strategy, and contributes the "Chinese solution" to global cancer treatment.